Errata Corrige

ERRATA CORRIGE C O N C O M I T A N T I N F E C T I O N O F H T L V - I A N D HIV-I: P R E V A L E N C E O F I g G A N D IgM A N T I B O D I E S I N W A S H I N G T O N , D.C. A R E A By K.S.S. CHANG et al., Vol. 4, No. 4, 426-434 On pages 428 and 431, figures 2 and 5 should be read as follows: 123456 (A) 123456 (C) 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 p66-p55-- (C) (A) p42 -p53-- p36-- p55-p42-- p24-- p24 -- p36-- p19-- p28 ... p26-p24 / p24 -- p19-p17-123456 (B) 123456 (D) 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 (D) IB) p24-- p24 - - p19-- p24-- Figure 1. - Western blot test with VDRL (-) serum samples (Group 1). Panels (A) and (B) show reactions of IgG and IgM antibodies against HTLV-I, respectively, while panels (C) and (D) illustrate reactions oflgG and IgM antibodies against HIV-1, respectively. Identical numbers in these four panels represent the same serum samples. ~ Figure 2. - Western blot test with sera from miscellaneous disease patients (Group 2). Legend is the same as in Figure 1. 128 Vol. 4, 1988 HTLV-I and HIV-1 concomitant infection As shown in Figures 5(C) and 5(D), among the 23 sera which were positive for IgG antibody against HIV-1, 15 (65.2%) (Nos. 1-4, 6, 8, 10, 13, 14, 16-19, 21 & 22) showed IgM antibody against HIV-1 also. This difference (25% versus 65.20/0) was statistically significant (p<0.05). Among those 8 persons who exhibited dual antibodies, 7 (87.5%) showed IgM antibody to HIV-1 also, as illustrated in Figure 5(C). It is of interest to note that one serum sample (No. 18) showed both IgG and IgM antibodies against both HTLV-I and HIV-1. These results suggest that for most of these drug abusers with dual antibodies, the time of HIV-1 infection appears to be more recent than that for HTLV-I as evidenced by the more frequent presence in their sera of IgM antibody against the former than against the latter virus, whether it is primary, or reinfection or recurrent infection. It may be argued that the apparent dual antibody reactions against both HTLV-I and HIV-1 may be due to the presence of putative cross-reacting antigens in the Western blots. In order to rule out this possibility, the following absorption experiments were performed. Two serum samples that contained antibodies against both HTLV-I and HIV-1 were absorbed repeatedly with either MT-2 cells producing HTLV-I, or H9 cells producing HIV-1. As shown in Table 4 and Figure 6, the results of immunofluorescence and Western blot tests indicated that the sera treated by absorption 1 2 3 4 5 6 ? 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 (C) (A) iii!iill gp160-- ~'~ p66 ... p55 .~. p51 -gp41 -- P53-p42 - p36-p32'- !?ii i,~i:ii iil ~ i!iill i!!ifii p24-- 1 2 3 4 5 6 7 8 91011121314151617181920212223 ?Ji 2 !iil p31 -- ii , p24 -- p19-- p17-- ~o iiii 1 2 3 4 56 7 891011121314151617181920212223 (B) D) 1 2 3 4 5 6 7 8 91011121314151617181920212223 gp160-- p 6 6 ... p55~ p51 - - p42 -- gp41 - - p31 - - p24-- p24 -p19-- p17-- Figure 5. - Western blot test with sera collected in 1985-86 from drug abusers positive for IgG antibody against HIV-1 (Group 5). Legend is the same as in Figure 1. 129  (...truncated)